Avalo Therapeutics at H.C. Wainwright conference: phase 2 data lift outlook
On 16 September 2026, Avalo Therapeutics (AVTX) presented data at the H.C. Wainwright 28th Annual Global Investment Conference. The data pertained to its lead drug, abdakibart, which has demonstrated promising results in Phase 2b trials for hidradenitis suppurativa (HS). HS is a painful inflammatory skin disease with limited effective treatments.
Avalo's abdakibart met the main goal in the LOTUS Phase 2b trial, showing improved efficacy compared to a placebo. The drug has a favorable safety profile and a monthly dosing schedule, potentially setting it apart from competitors. At the end of June 2024, Avalo had $472 million in cash and investments, providing sufficient funds to support the drug through potential Phase 3 testing.
The company also highlighted its pipeline, including the next-generation long-acting IL-1 beta antibody AVTX-010, and its assessment of the large, growing HS market, estimating it could exceed $10 billion by 2035.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
